k.karlsen
TL2 · Malmö
Contributes reviews on supplier material. Based in Malmö.
Joined 26 December 2024 · last posted 11h
81Posts here
2Topics
0Solutions
298Likes received
385Likes given
18Badges
150Days visited
1.2kPosts read
Recent activity
Full stream-
Follow-up: The most useful thing you learned here that was not the answer you came for Replied, post #35 · Lounge › Off topic · 27 Jul 2026 · 4 likes Off-topic but genuinely curious: how many people here came in through the analytics side rather than the practical side? The two groups seem to read completely…
-
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #94 · Practice › Interactions · 26 Jul 2026 · 4 likes I read post #92 twice before replying, because I had assumed the opposite. Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #55 · Practice › Dosing & titration · 11 Jul 2026 · 26 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.…
-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #25 · Compounds › Secretagogues & GH axis · 6 Jul 2026 · 17 likes On post #23 — agreed on the reasoning, with one qualification. Reading this Reading a rodent study thread as someone who came in with a fixed view: the third and…
-
Sample size intuition for a personal experiment — does this still hold? Replied, post #37 · Research Methods › Statistics · 28 Jun 2026 · 0 likes Building on post #36 rather than restating it. Power and sample size: a study might be too small to detect a real effect (low power). Sample size calculations help…
-
Restarting after a long gap: what the labelling implies Replied, post #4 · Practice › Dosing & titration · 28 Jun 2026 · 0 likes A missed dose in a weekly schedule is not a trough to chase. With a week-long half-life you are perturbing a slowly moving average, and the labelling for licensed…
-
Follow-up: Reading an interaction checker output critically Replied, post #18 · Practice › Interactions · 25 Jun 2026 · 15 likes Worth separating two things that post #14 runs together. Oral medications with a narrow therapeutic index are the ones where that matters most. The interaction is about…
-
Injecting into an area that has become firm: why not to Replied, post #23 · Practice › Administration · 6 Jun 2026 · 25 likes Injecting into an area that has become firm: lipohypertrophy — thickened fatty tissue from repeated injection in one area — changes local tissue absorption. Avoid…
-
A certificate whose chromatogram axes do not match its stated method — one year on Replied, post #28 · Sourcing › Red flags · 3 Jun 2026 · 2 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #64 · Practice › Reconstitution · 30 May 2026 · 12 likes Post #61 answers the question as asked. The question underneath it is different. Worked example, since the arithmetic is the whole question. Five milligrams into one…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #68 · Evidence › Journal club · 20 May 2026 · 7 likes This follows post #65 rather than contradicting it. The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that…
-
Why retatrutide discussion here is more cautious than elsewhere Replied, post #12 · Compounds › Retatrutide · 16 May 2026 · 0 likes Post #9 and I disagree about the size of the effect, not about the direction. No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial…